Leukemia | Topics

Avapritinib is now fully approved to treated advanced systemic mastocytosis, according to phase 1 and phase 2 clinical trial data.

A phase 2 trial evaluated the combination of vemurafenib plus rituximab, which produced a complete response in 87% of the evaluable patients with hairy-cell leukemia.

A study published in The Lancet Hematology found an increased risk of developing myelodysplastic syndrome and acute myeloid leukemia when patients with cancer were treated with PARP inhibitors compared with placebo.